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INTRODUCTION
Endoscopic submucosal dissection (ESD) is considered a 
standard treatment modality for early gastric cancer (EGC) 
that meets the absolute criteria.1 These absolute criteria have 
been expanded by Gotoda et al. based on pathological analysis 
of surgical specimen for risk factors of lymph node metastasis.2 
The expanded criteria are now recommended by the Japanese 
gastric cancer treatment guidelines3 and by the Korean guide-
lines.4 Such criteria have been used to determine both the fea-
sibility of ESD and its efficacy for cure. If the efficacy for cure 
is considered unclear, additional surgery is recommended. 
Many studies have investigated the feasibility and effectiveness 
of ESD in treating EGC.5-7
Gastric cancers with an undifferentiated histology display 
different biological behaviors from differentiated-type gastric 
cancers. They usually show higher lymph node metastasis 
rates and infiltrative growth.8 Recently published meta-analysis 
studies have revealed that endoscopic resection of EGC is not 
inferior to surgical resection.9-11 Although several studies have 
reported good long-term survival rates in patients with undif-
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ferentiated-type EGC (UD-EGC) after endoscopic resection, 
the use of endoscopy rather than surgery for the treatment of 
UD-EGC is still controversial.12-15
No systematic review has been published on the clinical 
outcomes of ESD compared with surgery in patients with UD-
EGC. The objective of this study was to perform a systematic 
review and meta-analysis to clarify the efficacy and safety of 
ESD and surgery for UD-EGC.
MATERIALS AND METHODS
Literature searching strategy
As this article is a systematic review and meta-analysis and 
does not include the patients’ personal information, ethical 
committee approval was not required. This systematic review 
and meta-analysis fully adhered to the principles of the Pre-
ferred Reporting Items for Systematic reviews and Meta-Anal-
yses (PRISMA) guidelines.16 This study was registered in the 
PROSPERO international database (www.crd.york.ac.uk/
PROSPERO; registration no. CRD42018107853).
The PubMed, Cochrane Library, and EMBASE databases 
were independently searched by two authors (CWH and 
DWM). The following search terms were used: “stomach can-
cer” OR “gastric cancer” OR “early gastric cancer” OR “early 
stomach cancer” OR “stomach neoplasm and endoscopic re-
section” OR “endoscopic mucosal resection” OR “endoscopic 
submucosal dissection” OR “EMR” OR “ESD and gastrec-
tomy” OR “surgery” OR “surgical procedure” OR “general 
surgery” OR “minimally invasive surgical procedures”. No lan-
guage restrictions were applied. A repetitive manual search of 
cited references in published studies was performed to identify 
additional studies.
Selection criteria
We included studies that met the following criteria: (1) in-
cluded participants with histologically diagnosed UD-EGC; 
(2) compared ESD and surgery for the treatment of UD-EGC; 
and (3) reported results that included at least two of the fol-
lowing endpoints: overall survival, recurrence, adverse event, 
and complete resection. Studies that met all of these inclusion 
criteria were sought and selected. The exclusion criteria were 
as follows: (1) review articles; (2) guidelines or consensus doc-
uments or expert position papers; (3) comments, letters, brief 
reports, and protocol studies; (4) case reports; (5) publications 
with incomplete data; or (6) meta-analysis articles.
Data extraction
Two authors (CWH and DWM) independently extracted 
data from the included studies using a pre-data extraction 
form. The titles and abstracts of all included studies were re-
viewed to exclude irrelevant publications. Differing decisions 
were resolved by consensus. If any clarification of data was 
necessary, more information was requested from the authors 
of each study. The following information was extracted: year 
of publication, name of the first author, sample size, trial inclu-
sion and exclusion criteria, length of follow-up, overall survival 
rate, recurrence rate, adverse event rate, and complete resec-
tion rate. Overall survival rate was defined as the percentage of 
patients who remained alive after ESD or surgery. Recurrence 
rate was defined as the percentage of patients who experienced 
a reappearance of gastric cancer after the initial treatment. Re-
currence was defined to include local recurrence, synchronous 
and metachronous recurrence, and extragastric recurrence. 
Adverse event was defined as any complication related to the 
treatment, such as major bleeding, perforation, dehiscence, 
and infection, during or after the procedure. Complete resec-
tion was defined as the total removal of gastric cancer using 
a surgical or an endoscopic approach without residual viable 
cells on procedure day.
Methodological quality
The methodological quality of the included studies was 
assessed using the Risk of Bias Assessment tool for Nonran-
domized Studies (RoBANS).17 The RoBANS tool contains six 
domains. It is a validated tool that is reliable and feasible for as-
sessing the methodological quality of nonrandomized studies. 
Two authors (CWH and DWM) independently assessed the 
methodological quality of the included studies. Any disagree-
ment between the two evaluators was resolved by discussion.
Statistical analysis
Data were analyzed using Review Manager version 5.3 
(RevMan for Windows 7; Nordic Cochrane Centre, Copen-
hagen, Denmark). The adverse events from each study were 
pooled. Odds ratios (ORs) and 95% confidence intervals (CIs) 
of dichotomous variables were obtained using a fixed-effect 
model or a random-effect model. Heterogeneity was deter-
mined using the I2 test developed by Higgins et al.,18 which 
measures the percentage of total variation across studies. I2 
was calculated as follows: I2 (%) = 100 × (Q - df) / Q, where 
Q is Cochrane’s heterogeneity statistic and df is the degree of 
freedom. Negative values for I2 were set to zero, and an I2 value 
of >50% was considered to indicate substantial heterogeneity 
(range, 0%–100%). Publication bias was evaluated using Begg’s 
funnel plot and Egger’s test of intercept.19,20 A subsequent assay 
was performed, excluding outliers. Other findings were com-





Our search strategy extracted a total of 527 papers (PubMed, 
n =156; Cochrane Library, n =9; EMBASE, n =362). Du-
plicated articles (n =148) were excluded. An additional 349 
studies were excluded during the initial screening of titles and 
abstracts. Thereafter, the full texts of the remaining 30 studies 
were thoroughly reviewed. Among these studies, 25 articles 
were excluded from the final analysis for the following rea-
sons: no endpoint of interest (n=15), few patients with UD-
EGC (n=8), and irrelevant ESD or gastrectomy (n=2). The 
remaining five studies were included in the final quantitative 
analysis. The detailed flow diagram illustrating the study selec-
tion process is shown in Fig. 1.
Characteristics of the included studies
The main characteristics of the included studies are listed 
in Table 1.21-25 A total of 1,665 patients were included, with 
429 and 1,236 in the ESD and surgery arms, respectively. All 
articles were retrospective studies from Korea. They were 
published within the last 5 years (from 2014 to 2019). Chung 
et al. reported the long-term outcomes of ESD compared 
with those of surgical treatment in patients with UD-EGC.25 
They also included some ESD cases that were beyond the 
expanded indications (23.7%). The complete resection rates 
for the absolute criteria group and the beyond criteria group 
were 86.2% and 44.4%, respectively (p <0.05). The total re-
currence rates in the ESD group and the surgery group were 
14.1% (total, n=9; local recurrence, n=1; synchronous and 
metachronous recurrence, n=7; extragastric recurrence, n=1) 
and 0.7% (total, n=1, metachronous recurrence), respectively 
(p<0.05). Lee et al. compared the long-term outcomes of ESD 
and surgery for EGC under the expanded indications based 
on each criterion.23 They selected 522 patients in each group 
through propensity score matching and retrospectively eval-
uated each group. In their study, the UD-EGC group showed 
similar overall survival and recurrence-free survival rates to 
the other groups. Thus, the authors stated that ESD may be an 
alternative treatment option to surgery for EGC meeting the 
expanded indications, including UD-EGC. Hahn et al. aimed 
to compare the short- and long-term outcomes between ESD 
and surgery in patients with EGC that fulfilled the expanded 
criteria for ESD on their final pathological report.24 They ana-
lyzed 2,203 patients who underwent ESD or surgery for EGC. 
In the ESD and surgery groups, 92 and 561 patients were 





















Records identified through database searching·
• PubMed (n=156)
• EMBASE (n=362)
• Cochrane Library (n=9)
Records after duplicates removed (n=379)
Records screened (n=379) Records excluded (n=349)
Additional records identified
through other sources (n=0)
Full-text articles assessed for eligibility (n=30)




• No interested endpoint (n=15)
• Few patients with Uildifferentiated EGC (n=8)
• Not about ESD and gastrectomy (n=2)
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diagnosed with UD-EGC, respectively. The overall survival 
and disease-specific survival rates were similar between the 
ESD and surgery groups. However, cancer recurrence was sig-
nificantly higher in the ESD group than in the surgery group 
(hazard ratio, 12.801; 95% CI, 6.074–26.978; p<0.001). Park 
et al. showed the long-term outcomes of ESD and surgery for 
UD-EGC using propensity score analysis.22 The clinical data 
from 111 patients who underwent ESD and 382 patients who 
underwent surgery were analyzed, and 1:1 propensity score-
matched 81 pairs of patients were compared. Overall survival 
was not significantly different between the two groups in the 
overall comparison and in propensity score-matched analysis. 
However, the total recurrence rate was significantly higher in 
the ESD group than in the surgery group (ESD group, n=11 
[local recurrence, n=9; synchronous and metachronous re-
currence, n=2] vs. surgery group, n=0). Lim et al. showed the 
long-term outcomes of ESD and surgery for UD-EGC using 
propensity score matching.21 After 1:4 propensity score match-
ing, they compared 102 patients from the ESD group and 372 
patients from the surgery group. They included cases that 
were beyond the expanded indications (ESD: 52.9%, surgery: 
59.7%). Overall survival and disease-specific survival were 
similar between the ESD and surgery groups. However, the 
disease-free survival rate was lower in the ESD group because 
of the higher rate of metachronous cancer recurrence (hazard 
ratio, 14.27; 95% CI, 3.07–66.31; p=0.001). Ten patients (9.8%) 
in the ESD group experienced recurrence (local recurrence, 
n=4; metachronous recurrence, n=6), whereas two patients 
(0.5%) in the surgery group had recurrence (metachronous re-
currence, n=1; extragastric recurrence, n=1). In multivariate 
analysis, treatment option was not related to overall survival 
(hazard ratio for ESD over surgery, 1.12; 95% CI, 0.41–3.05; 
p=0.831).
Methodological quality
The methodological quality of the included studies was 
similar (Fig. 2). One study had a high risk for confounding 
variables. The study did not show a comparison of baseline 
Fig. 2. Risk of bias of the enrolled studies. 



























































































Hahn et al. 
(2018)24
Lee et al. 
(2018)23
Lim et al. 
(2019)21
Park et al. 
(2018)22
+ + − + + + + +
+ + + + + + + +
+ + + + + + + +
+ + + + + + + +
+ + + + + + + +
Table 1. Baseline Characteristics of Included Studies
Study Study design Patients Inclusion criteria Follow up (mo) End points 
Chung et al. 
(2014)25 
Retrospective ESD: 76 
Surgery: 149 
ESD: EI (76.3%), 
beyond EI (23.7%) 
Surgery: EI, no LNM 
ESD: 41.7±22.6 
Surgery: 42.8±17.3 
En bloc resection, complete resec-
tion, complication, recurrence rate, 
mortality 
Lee et al. 
(2018)23 




ESD: 52.7 (37.7–67.9) 
Surgery: 59.2 (47.9–63.4) 
Overall survival, recurrence free 
survival, complication, hospital 
stay 
Hahn et al. 
(2018)24 




ESD: 37.5 (26.3–59.4) 
Surgery: 57.3 (37.6–60.5) 
Overall survival, disease-specific 
survival, cancer recurrence, com-
plication 
Park et al. 
(2018)22 




ESD: 48.1 (33.6–71.4) 
Surgery: 60.0 (34.0–70.1) 
Overall survival, disease free surviv-
al, complication, hospital stay, en 
bloc resection, complete resection 
Lim et al. 
(2019)21 




ESD: 65.9 (48.8-97.4) 
Surgery: 58.3 (42.3-72.0)  
Overall survival, disease free sur-
vival, metachronous recurrence, 
local recurrence 
EI, expanded indication; ESD, endoscopic submucosal dissection; LNM, lymph node metastasis.
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characteristics between two arms.25
Comparison of outcomes
Complete resection data were available for five studies re-
porting the information of 1,665 patients (Fig. 3). Pooled anal-
ysis demonstrated that the complete resection rate was much 
higher in the surgery group than in the ESD group (OR, 42.86; 
95% CI, 13.06–140.69; p<0.001). The heterogeneity was low 
(I2 =11%).
Adverse event data were available for three studies reporting 
the information of 966 patients (Fig. 4). Pooled analysis re-
vealed that the adverse event rate was similar between the ESD 
and surgery groups (OR, 0.48; 95% CI, 0.20–1.13; p=0.09). 
The heterogeneity was high (I2 =80%). A funnel plot was 
drawn, and one outlier was detected.24 After excluding this 
study, heterogeneity persisted (I2 =69%). When a random-ef-
fect model was applied, the same finding was obtained.
Recurrence data were available for five studies reporting 
the information of 1,653 patients (Fig. 5). Pooled analysis 
demonstrated that the recurrence rate was much higher in 
the ESD group than in the surgery group (OR, 15.82; 95% CI, 
7.03–35.60; p<0.001). The heterogeneity was low (I2 =0%).
Surgery ESD Odds ratio
Study Events Total Events Total Weight M-H, Random, 95% CI
Chung et al. (2014)25 149 149 58 76 18.2% 94.56 [5.61, 1,594.66]
Hahn et al. (2018)24 561 561 79 92 18.1% 90.70 [11.23, 3,239.31]
Lee et al. (2018)23 73 73 77 78 14.4% 2.58 [0.11, 70.96]
Park et al. (2018)22 81 81 73 81 17.7% 18.85 [1.07, 332.31]
Lim et al. (2019)21 371 372 88 102 31.7% 59.02 [7.66, 454.84]
Total (95% CI) 1,236 429 100.0% 42.02 [11.74, 150.36]
Total events 1,235 375
Heterogeneity: Tau2=0.25; Chi2=4.53, df=4 (p=0.34); I2=12%
Test for overall effect: Z=5.75 (p<0.00001)
Odds ratio
M-H, Random, 95% CI
0.001 0.1 101
Favours [ESD] Favours [Surgery]
1000
Fig. 3. Forest plot of complete resection rate comparing endoscopic submucosal dissection (ESD) and surgery. CI, confidence interval.
Surgery ESD Odds ratio
Study Events Total Events Total Weight M-H, Random, 95% CI
Hahn et al. (2018)24 3 92 94 561 37.1% 0.17 [0.05, 0.54]
Lee et al. (2018)23 3 78 4 73 34.1% 0.69 [0.15, 3.19]
Park et al. (2018)22 7 81 1 81 28.8% 7.57 [0.91, 62.98]
Total (95% CI) 251 751 100.0% 0.81 [0.11, 6.07]
Total events 13 99
Heterogeneity: Tau2=2.48; Chi2=9.84, df=2 (p=0.007); I2=80%
Test for overall effect: Z=0.20 (p=0.84)
Odds ratio
M-H, Random, 95% CI
0.001 0.1 101
Favours [ESD] Favours [Surgery]
1000
Fig. 4. Forest plot of adverse event rate comparing endoscopic submucosal dissection (ESD) and surgery. CI, confidence interval.
Surgery ESD Odds ratio
Study Events Total Events Total Weight M-H, Random, 95% CI
Chung et al. (2014)25 9 64 1 149 15.1% 24.22 [3.00, 195.61]
Park et al. (2018)22 11 81 0 81 8.1% 26.59 [1.54, 459.34]
Hahn et al. (2018)24 8 92 3 561 36.3% 17.71 [4.61, 68.10]
Lee et al. (2018)23 3 78 1 73 12.6% 2.88 [0.29, 28.33]
Lim et al. (2019)21 10 102 2 372 27.9% 20.11 [4.33, 93.35]
Total (95% CI) 417 1236 100.0% 15.82 [7.03, 35.60]
Total events 41 7
Heterogeneity: Tau2=0.00; Chi2=2.54, df=4 (p=0.64); I2=0%
Test for overall effect: Z=6.67 (p<0.00001)
Odds ratio
M-H, Random, 95% CI
0.001 0.1 101
Favours [ESD] Favours [Surgery]
1000
Fig. 5. Forest plot of recurrence rate comparing endoscopic submucosal dissection (ESD) and surgery. CI, confidence interval.
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Fig. 7. Subgroup analysis in undifferentiated-type early gastric cancer within the expanded indications. (A) Forest plot of overall survival rate. (B) Forest plot of 
recurrence rate. (C) Forest plot of complete resection rate. CI, confidence interval; ESD, endoscopic submucosal dissection.
Surgery ESD Odds ratio
Study Events Total Events Total Weight M-H, Random, 95% CI
Lee et al. (2018)23 73 73 78 78 Not estimable
Hahn et al. (2018)24 555 561 89 92 74.5% 3.12 [0.77, 12.69]
Lim et al. (2019)21 277 282 48 48 25.5% 0.52 [0.03, 9.56]
Total (95% CI) 916 218 100.0% 1.98 [0.40, 9.66]
Total events 905 215
Heterogeneity: Tau2=0.37; Chi2=1.27, df=1 (p=0.26); I2=21%
Test for overall effect: Z=0.84 (p=0.40)
Odds ratio
M-H, Random, 95% CI
0.01 0.1 101
Favours [ESD] Favours [Surgery]
100
Surgery ESD Odds ratio
Study Events Total Events Total Weight M-H, Random, 95% CI
Hahn et al. (2018)24 561 561 79 92 35.0% 190.70 [11.23, 3,239.31]
Park et al. (2018)22 81 81 73 81 34.5% 18.85 [1.07, 332.31]
Lee et al. (2018)23 73 73 77 78 30.5% 2.85 [0.11, 70.96]
Total (95% CI) 715 251 100.0% 23.77 [2.23, 252.83]
Total events 715 229
Heterogeneity: Tau2=2.07; Chi2=3.81, df=2 (p=0.15); I2=47%
Test for overall effect: Z=2.63 (p=0.009)
Odds ratio
M-H, Random, 95% CI
0.01 0.1 101
Favours [ESD] Favours [Surgery]
100
Surgery ESD Odds ratio
Study Events Total Events Total Weight M-H, Random, 95% CI
Lee et al. (2018)23 3 78 1 73 18.5% 2.88 [0.29, 28.33]
Park et al. (2018)22 11 81 0 81 11.9% 26.59 [1.54, 459.34]
Hahn et al. (2018)24 8 92 3 561 53.2% 17.71 [4.61, 68.10]
Lim et al. (2019)21 2 48 1 282 16.5% 12.22 [1.09, 137.48]
Total (95% CI) 299 997 100.0% 12.51 [4.68, 33.39]
Total events 24 5
Heterogeneity: Tau2=0.00; Chi2=2.11, df=3 (p=0.55); I2=0%
Test for overall effect: Z=5.04 (p<0.00001)
Odds ratio
M-H, Random, 95% CI
0.01 0.1 101






M-H, Random, 95% CI
0.001 0.1 101
Favours [ESD] Favours [Surgery]
1000
Surgery ESD Odds ratio
Study Events Total Events Total Weight M-H, Random, 95% CI
Chung et al. (2014)25 147 149 64 64 7.8% 0.46 [0.02, 9.66]
Hahn et al. (2018)24 555 561 89 92 36.6% 3.12 [0.77, 12.69]
Lee et al. (2018)23 73 73 78 78 Not estimable
Lim et al. (2019)21 364 372 97 102 55.6% 2.35 [0.75, 7.33]
Total (95% CI) 1,155 336 100.0% 2.29 [0.98, 5.36]
Total events 1,139 328
Heterogeneity: Tau2=0.00; Chi2=1.30, df=2 (p=0.52); I2=0%
Test for overall effect: Z=1.91 (p=0.06)
Fig. 6. Forest plot of overall survival rate comparing endoscopic submucosal dissection (ESD) and surgery. CI, confidence interval.
Overall survival data were available for four studies report-
ing the information of 1,491 patients (Fig. 6). The pooled anal-
ysis revealed that the overall survival rate was similar between 
the ESD and surgery groups (OR, 2.29; 95% CI, 0.98–5.36; 
p=0.06). The heterogeneity was low (I2 =0%). 
We also performed subgroup analysis among studies with-
in the expanded indications.21 In this subgroup analysis, the 
overall survival rate was similar between the ESD and surgery 
groups (OR, 1.83; 95% CI, 0.55–6.12; p=0.33). The ESD group 
showed a higher recurrence rate and a lower complete resec-
tion rate than the surgery group (Fig. 7). 
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DISCUSSION
ESD is currently considered the standard treatment for 
EGC that meets the absolute criteria of the Japanese gastric 
cancer treatment guidelines.3,4 However, these absolute criteria 
might be too strict, leading to unnecessary surgeries. This has 
resulted in the expansion of the criteria.6,26,27 On the basis of 
retrospective studies on surgical resection of EGC, expanded 
criteria have been established.2,3,7 Unfortunately, there are dis-
crepancies between pre- and post-ESD indications or histolo-
gy.28-30 ESD performed according to the expanded criteria can 
be beyond the expanded criteria after the procedure. A more 
serious problem is the difficulty in determining the tumor 
extent and the depth of invasion of UD-EGC. The accuracy of 
endoscopic ultrasound for estimating the depth of invasion in 
UD-EGC is known to be lower than that in differentiated-type 
EGC.31 It is difficult to accurately define the tumor extent and 
depth of invasion in UD-EGC.
In our meta-analysis, the overall survival rate was similar 
between the ESD and surgery groups. However, the recur-
rence rate was much higher in the ESD group. Most previous 
studies reported that the overall survival rate of patients with 
UD-EGC treated with ESD was approximately 90% until the 
end of follow-up.14,32-34 The interval of surveillance with esoph-
agogastroduodenoscopy after ESD and after surgery was not 
identical in most studies. In the current study, the most com-
mon recurrence type in the ESD group was metachronous re-
currence. Repeated ESD is an effective treatment modality for 
local and metachronous recurrence. Surgery is also a success-
ful treatment modality, especially in the presence of regional 
lymph node recurrence.35 Several studies have revealed that 
metachronous lesions can be effectively detected by endoscop-
ic surveillance in the early stage and cured by repeated ESD 
or surgery.28,36 This may be the reason why the overall survival 
rate in the ESD group was not inferior to that in the surgery 
group, although the ESD group had a higher recurrence rate. 
This suggests that meticulous surveillance after ESD may be 
as effective and safe as surgery in patients with UD-EGC. 
Although the overall survival was not significantly different 
between the ESD and surgery groups, the surgery group tend-
ed to have better overall survival (OR, 2.29; 95% CI, 0.98–5.36; 
p=0.06). Conversely, this tendency was significantly decreased 
in subgroup analysis among patients with UD-EGC within the 
expanded indications (OR, 1.83; 95% CI, 0.55–6.12; p=0.33). 
Therefore, more meticulous surveillance may be needed, espe-
cially for UD-EGC beyond the expanded indications.
Surgery is generally considered to be associated with more 
adverse events than ESD. However, in the present study, no 
difference in adverse events was observed between the two 
groups. Significant heterogeneity existed among the enrolled 
studies.22-24 The pooled adverse event rate for endoscopic 
resection was 5.7%, with bleeding and perforation being the 
most common complications. Most cases of bleeding and per-
foration can be conservatively managed with electrocoagula-
tion, insulated-tip knife, or metal clips. Uncontrolled bleeding 
or perforation may require surgery. In contrast, complications 
associated with gastrectomy, including dehiscence, major 
bleeding, and infection, can lead to mortality. It should be 
remembered that not all the complications after surgery were 
described in each study included in this meta-analysis, sug-
gesting that surgical complication rates may have been under-
estimated. For example, delayed complications after surgery, 
such as stricture and leakage from the anastomosis site, were 
not fully described.
Although this is the first systematic review and meta-anal-
ysis to compare ESD and surgery for UD-EGC, it had several 
limitations. First, all included studies were retrospective in 
nature without randomization, meaning that clinicopath-
ological characteristics such as invasion depth, histological 
differentiation, and tumor size could not be perfectly matched. 
This could lead to considerable selection bias. Second, UD-
EGC included poorly differentiated adenocarcinoma, signet 
ring cell carcinoma, and mucinous adenocarcinoma.37 Poorly 
differentiated adenocarcinoma and mucinous adenocarcino-
ma are known to be associated with higher lymph node me-
tastasis than signet ring cell carcinoma.38-40 Thus, incomplete 
pathological subgroup analysis might have affected the results. 
Third, the included studies were all from Korea, where the 
incidence of gastric cancer and the detection rate of EGC are 
relatively high. The situation in Western countries remains 
unknown. Further studies from other countries are needed to 
validate the results of our study. Fourth, some data, including 
overall survival rate and adverse event rate, were not provid-
ed in some studies, which weakened the interpreting power 
of our results. Fifth, because there was high heterogeneity in 
some analyses, care should be taken when interpreting our 
results. Finally, we could not evaluate publication bias owing 
to the small number of studies included. As a rule of thumb, 
tests for publication bias should be used only when at least 10 
studies are included in the meta-analysis.
In conclusion, this meta-analysis showed that ESD with 
meticulous surveillance esophagogastroduodenoscopy may 
be as effective and safe as surgery in patients with UD-EGC, 
especially for cases within the expanded criteria. Further large-
scale randomized, controlled studies from additional regions 
are required to confirm these findings.
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